株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州の多発性硬化症市場

Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals)

発行 Renub Research 商品コード 565308
出版日 ページ情報 英文 86 Pages; 73 Figures; 1 Table
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
欧州の多発性硬化症市場 Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals)
出版日: 2017年10月06日 ページ情報: 英文 86 Pages; 73 Figures; 1 Table
概要

欧州の多発性硬化症市場規模は、2022年までに50億米ドルを上回る可能性があります。

当レポートでは、欧州の多発性硬化症市場について調査分析し、地域全体および主要国における患者数と予測、投与形態別による患者数と予測、および成長促進因子と課題の分析など、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 欧州の多発性硬化症患者数

  • 患者数 & 予測
  • 病態修飾療法 (DMT) 患者数 & 予測
  • 投与形態:DMT患者数 & 予測
    • 注射剤
    • 点滴
    • 経口薬

第3章 欧州の多発性硬化症市場

  • アンメットニーズ & 予測
  • 市場 & 予測
  • 投与形態:市場 & 予測
    • 注射剤
    • 点滴
    • 経口薬

第4章 欧州の多発性硬化症人口シェア

  • 患者数シェア & 予測
  • 病態修飾療法 (DMT) 患者数シェア & 予測
  • 投与形態:DMT患者数シェア & 予測

第5章 欧州の多発性硬化症市場シェア

  • 国別:アンメット市場シェア & 予測
  • 国別:市場シェア & 予測
  • 投与形態:市場シェア & 予測

第6章 英国

  • 多発性硬化症患者数
    • 患者数 & 予測
    • DMT患者数 & 予測
  • 多発性硬化症市場
    • アンメット市場 & 予測
    • 市場 & 予測

第7章 フランス

第8章 ドイツ

第9章 イタリア

第10章 スペイン

第11章 成長促進因子

第12章 課題

第13章 付録

図表

目次

Europe multiple sclerosis market potential is of more than US$ 5 Billion by 2022. But only more than half this market is expected to be actually achieved. This huge difference between actual market and unmet market is due to gap between number of patients who require multiple sclerosis drugs and number of patients who are receiving disease modifying therapy.

Orals mode of administration is Fast growing disease modifying therapy in the European region

Orals mode of administration is fast growing disease modifying therapy in the European region. Injectables and infusions multiple sclerosis therapies are steadily losing their ground in the European market.

Germany is the clear winner in the Europe multiple sclerosis market

In the Europe multiple sclerosis market, Germany is the clear winner, but its losing its market share year on year. The other important markets in the European region are France, Italy, Spain and United Kingdom.

Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals) published by Renub Research on Multiple Sclerosis Market. This 86 page report with 73 figures and 1 Tables provides 5 Countries: actual and unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.

  • Actual Market is the current market which is already present
  • Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

Top 5 Countries Multiple Sclerosis Market & Patients Treated

  • 1. United Kingdom
  • 2. Germany
  • 3. France
  • 4. Italy
  • 5. Spain

Mode of administration - Market & Patients Treated

  • 1. Injectables
  • 2. Infusions
  • 3. Orals

Key Questions Answered in the Report?

  • What is the Europe multiple sclerosis market and its growth potential in near future?
  • How many number of patients treated by disease modifying therapy in the European region?
  • What is the multiple sclerosis market in European countries (UK, Germany, France, Italy, and Spain)?
  • How many multiple sclerosis patients living in European countries?
  • Which mode of administration (Injectables, Infusions, Orals) is gaining more popularity?

Table of Contents

1. Executive Summary

2. Europe Multiple Sclerosis Patient Numbers (2011-2022)

  • 2.1. Patient Number & Forecast
  • 2.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 2.3. By Mode of Administration-Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
    • 2.3.1. Injectables Patients Numbers
    • 2.3.2. Infusions Patients Numbers
    • 2.3.3. Orals Patient Numbers

3. Europe Multiple Sclerosis Market (2011-2022)

  • 3.1. Unmet Market & Forecast
  • 3.2. Market & Forecast
  • 3.3. By Mode of Administration-Market & Forecast
    • 3.3.1. Injectables Market
    • 3.3.2. Infusions Market
    • 3.3.3. Orals Market

4. Europe Multiple Sclerosis Population Share (2011-2022)

  • 4.1. Patient Numbers Share & Forecast
  • 4.2. Disease-Modifying Therapy (DMT) Patient Numbers Share & Forecast
  • 4.3. By Mode of Administration-Patient Numbers Share & Forecast

5. Europe Multiple Sclerosis Market Share (2011-2022)

  • 5.1. By Countries-Unmet Market Share & Forecast
  • 5.2. By Countries-Market Share & Forecast
  • 5.3. By Mode of Administration Market Share & Forecast

6. United Kingdom

  • 6.1. Multiple Sclerosis Patient Numbers (2011-2022)
    • 6.1.1. Patient Number & Forecast
    • 6.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 6.2. Multiple Sclerosis Market (2011-2022)
    • 6.2.1. Unmet Market & Forecast
    • 6.2.2. Market & Forecast

7. France

  • 7.1. Multiple Sclerosis Patient Number (2011-2022)
    • 7.1.1. Patient Number & Forecast
    • 7.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 7.2. Multiple Sclerosis Market (2011-2022)
    • 7.2.1. Unmet Market & Forecast
    • 7.2.2. Market & Forecast

8. Germany

  • 8.1. Multiple Sclerosis Patient Number (2011-2022)
    • 8.1.1. Patient Number & Forecast
    • 8.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 8.2. Multiple Sclerosis Market (2011-2022)
    • 8.2.1. Unmet Market & Forecast
    • 8.2.2. Market & Forecast

9. Italy

  • 9.1. Multiple Sclerosis Patient Number (2011-2022)
    • 9.1.1. Patient Number & Forecast
    • 9.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 9.2. Multiple Sclerosis Market (2011-2022)
    • 9.2.1. Unmet Market & Forecast
    • 9.2.2. Market & Forecast

10. Spain

  • 10.1. Multiple Sclerosis Patient Number (2011-2022)
    • 10.1.1. Patient Number & Forecast
    • 10.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 10.2. Multiple Sclerosis Market (2011-2022)
    • 10.2.1. Unmet Market & Forecast
    • 10.2.2. Market & Forecast

11. Growth Drivers

  • 11.1. Point no. 1

12. Challenges

  • 12.1. Point no. 1
  • 12.2. Point no. 2
  • 12.3. Point no. 3

13. Appendix

List of Figures:

  • Figure 2-1: Europe - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-2: Europe - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-3: Europe - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-4: Europe - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-5: Europe - Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-6: Europe - Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-7: Europe - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-8: Europe - Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-9: Europe - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-10: Europe - Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 - 2022
  • Figure 3-1: Europe - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 3-2: Europe - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 3-3: Europe - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 3-4: Europe - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 3-5: Europe - Multiple Sclerosis Injectables Market (Million US$), 2011 - 2016
  • Figure 3-6: Europe - Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 - 2022
  • Figure 3-7: Europe - Multiple Sclerosis Infusions Market (Million US$), 2011 - 2016
  • Figure 3-8: Europe - Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 - 2022
  • Figure 3-9: Europe - Multiple Sclerosis Orals Market (Million US$), 2011 - 2016
  • Figure 3-10: Europe - Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 - 2022
  • Figure 4-1: Europe - Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-2: Europe - Forecast for Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-3: Europe - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-4: Europe - Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-5: Europe - Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-6: Europe - Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-7: Europe - Multiple Sclerosis Unmet Market Share (Percent), 2011 - 2016
  • Figure 4-8: Europe - Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 - 2022
  • Figure 4-9: Europe - Multiple Sclerosis Market Share (Percent), 2011 - 2016
  • Figure 4-10: Europe - Forecast for Multiple Sclerosis Market Share (Percent), 2017 - 2022
  • Figure 4-11: Europe - Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 - 2016
  • Figure 4-12: Europe - Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 - 2022
  • Figure 5-1: United Kingdom - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 5-2: United Kingdom - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 5-3: United Kingdom - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 5-4: United Kingdom - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 5-5: United Kingdom - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 5-6: United Kingdom - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 5-7: United Kingdom - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 5-8: United Kingdom - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 6-1: France - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 6-2: France - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 6-3: France - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 6-4: France - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 6-5: France - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 6-6: France - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 6-7: France - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 6-8: France - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 7-1: Germany - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 7-2: Germany - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 7-3: Germany - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 7-4: Germany - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 7-5: Germany - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 7-6: Germany - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 7-7: Germany - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 7-8: Germany - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 8-1: Italy - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 8-2: Italy - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 8-3: Italy - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 8-4: Italy - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 8-5: Italy - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 8-6: Italy - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 8-7: Italy - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 8-8: Italy - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 9-1: Spain - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 9-2: Spain - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 9-3: Spain - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 9-4: Spain - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 9-5: Spain - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 9-6: Spain - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 9-7: Spain - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 9-8: Spain - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 11- 1: Europe - Number of Neurologists per 100,000 Specialized in MS Vs. Percent of MS Population Receiving DMDs, 2013
Back to Top